Beijing Tongrentang Co., Ltd

XSSC:600085 Stock Report

Market Cap: CN¥53.8b

Beijing Tongrentang Valuation

Is 600085 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600085 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600085 (CN¥39.22) is trading above our estimate of fair value (CN¥13.65)

Significantly Below Fair Value: 600085 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600085?

Key metric: As 600085 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600085. This is calculated by dividing 600085's market cap by their current earnings.
What is 600085's PE Ratio?
PE Ratio33x
EarningsCN¥1.63b
Market CapCN¥53.79b

Price to Earnings Ratio vs Peers

How does 600085's PE Ratio compare to its peers?

The above table shows the PE ratio for 600085 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.6x
002422 Sichuan Kelun Pharmaceutical
16.3x11.4%CN¥48.4b
000661 Changchun High-Tech Industry (Group)
11.8x22.0%CN¥43.6b
600196 Shanghai Fosun Pharmaceutical (Group)
33.1x30.1%CN¥62.8b
000999 China Resources Sanjiu Medical & Pharmaceutical
17.2x11.2%CN¥58.6b
600085 Beijing Tongrentang
33x15.8%CN¥53.8b

Price-To-Earnings vs Peers: 600085 is expensive based on its Price-To-Earnings Ratio (33x) compared to the peer average (19.6x).

Price to Earnings Ratio vs Industry

How does 600085's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600085 33.0xIndustry Avg. 29.9xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600085 is expensive based on its Price-To-Earnings Ratio (33x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 600085's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600085 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33x
Fair PE Ratio29.6x

Price-To-Earnings vs Fair Ratio: 600085 is expensive based on its Price-To-Earnings Ratio (33x) compared to the estimated Fair Price-To-Earnings Ratio (29.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600085 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥39.22
CN¥49.35
+25.8%
16.3%CN¥60.00CN¥30.00n/a9
Nov ’25CN¥40.40
CN¥48.24
+19.4%
17.3%CN¥60.00CN¥30.00n/a9
Oct ’25CN¥42.06
CN¥48.23
+14.7%
17.7%CN¥60.00CN¥30.00n/a9
Sep ’25CN¥35.17
CN¥52.54
+49.4%
15.2%CN¥60.85CN¥34.00n/a9
Aug ’25CN¥36.24
CN¥52.54
+45.0%
15.2%CN¥60.85CN¥34.00n/a9
Jul ’25CN¥39.25
CN¥53.60
+36.6%
14.4%CN¥60.85CN¥34.00n/a9
Jun ’25CN¥44.57
CN¥54.27
+21.8%
14.8%CN¥65.00CN¥35.00n/a9
May ’25CN¥42.33
CN¥53.25
+25.8%
15.4%CN¥65.00CN¥35.00n/a9
Apr ’25CN¥41.80
CN¥58.69
+40.4%
17.3%CN¥71.55CN¥37.00n/a9
Mar ’25CN¥44.00
CN¥61.40
+39.5%
16.7%CN¥72.45CN¥37.00n/a9
Feb ’25CN¥42.58
CN¥63.07
+48.1%
14.7%CN¥72.45CN¥40.00n/a9
Jan ’25CN¥53.70
CN¥61.29
+14.1%
18.1%CN¥72.45CN¥40.00n/a9
Dec ’24CN¥52.76
CN¥61.18
+16.0%
18.5%CN¥72.45CN¥39.00n/a9
Nov ’24CN¥51.65
CN¥60.60
+17.3%
18.0%CN¥72.45CN¥39.00CN¥40.409
Oct ’24CN¥54.78
CN¥61.49
+12.2%
19.2%CN¥75.09CN¥39.00CN¥42.069
Sep ’24CN¥55.29
CN¥60.26
+9.0%
23.9%CN¥75.09CN¥36.00CN¥35.177
Aug ’24CN¥51.49
CN¥58.55
+13.7%
23.3%CN¥75.09CN¥35.00CN¥36.247
Jul ’24CN¥57.56
CN¥54.07
-6.1%
24.7%CN¥66.33CN¥35.00CN¥39.255
Jun ’24CN¥59.09
CN¥53.27
-9.9%
27.3%CN¥66.33CN¥31.00CN¥44.575
May ’24CN¥58.16
CN¥51.06
-12.2%
25.5%CN¥66.33CN¥31.00CN¥42.335
Apr ’24CN¥55.14
CN¥47.71
-13.5%
26.1%CN¥61.58CN¥31.00CN¥41.805
Mar ’24CN¥48.96
CN¥47.28
-3.4%
25.6%CN¥61.58CN¥31.00CN¥44.005
Feb ’24CN¥47.13
CN¥47.28
+0.3%
25.6%CN¥61.58CN¥31.00CN¥42.585
Jan ’24CN¥44.68
CN¥46.88
+4.9%
25.6%CN¥61.58CN¥31.00CN¥53.705
Dec ’23CN¥49.15
CN¥45.96
-6.5%
23.8%CN¥56.98CN¥31.00CN¥52.765
Nov ’23CN¥47.30
CN¥48.11
+1.7%
25.0%CN¥59.78CN¥32.00CN¥51.655

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

7D

-1.4%

1Y

-24.4%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.30

7D

1.8%

1Y

13.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

7D

-2.4%

1Y

12.8%